Weber H P, Aberfeld U, Hildenbrand G, Knöpfle G
Dtsch Med Wochenschr. 1982 Jun 18;107(24):837-41.
28 children with initial episodes of urinary tract infection were treated with cotrimoxazole or cotrifamole (dose ratio 3 : 2) for 14 days in a prospective randomized double blind trial. The two groups did not differ as regards clinical signs. The efficacy and cure rates of each regimen were similar. Laboratory studies (hemoglobin, WBC, liver, and renal function) showed no differences between both groups before and after therapy; an alteration of the laboratory values could not be observed during therapy. The number of children with X-ray abnormalities of kidneys and urinary tract was similar in both groups. During an observation time of up to 12 months after the first urinary tract infection no differences in the number of reinfections and relapses were observed. As a result of this study, we recommend cotrifamole in a lower dose (ratio 2 : 3) than cotrimoxazole for the treatment of urinary tract infection.
在一项前瞻性随机双盲试验中,对28例初次发生尿路感染的儿童使用复方新诺明或复方磺胺嘧啶(剂量比3:2)治疗14天。两组在临床症状方面无差异。每种治疗方案的疗效和治愈率相似。实验室检查(血红蛋白、白细胞、肝功能和肾功能)显示两组治疗前后无差异;治疗期间未观察到实验室值的变化。两组中肾脏和尿路X线异常的儿童数量相似。在首次尿路感染后的长达12个月的观察期内,再感染和复发的数量没有差异。根据这项研究的结果,我们推荐使用比复方新诺明剂量更低(比例2:3)的复方磺胺嘧啶来治疗尿路感染。